## Nivolumab in melanoma: latest evidence and clinical po

Therapeutic Advances in Medical Oncology 7, 97-106 DOI: 10.1177/1758834014567469

Citation Report

#	Article	IF	CITATIONS
1	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. Sensors, 2015, 15, 16281-16313.	3.8	140
2	Current and Emerging Perspectives on Immunotherapy for Melanoma. Seminars in Oncology, 2015, 42, S3-S11.	2.2	19
3	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Review of Anticancer Therapy, 2015, 15, 981-993.	2.4	59
4	The current management of brain metastasis in melanoma: a focus on riluzole. Expert Review of Neurotherapeutics, 2015, 15, 779-792.	2.8	12
5	Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors. Oncotarget, 2016, 7, 58331-58350.	1.8	38
6	Immune Checkpoint Blockade Therapy: Merits and Demerits. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	0
7	Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent. Ecancermedicalscience, 2016, 10, 610.	1.1	80
9	Hydrogen Sulfide Pathway and Cancer. , 2016, , 133-144.		2
10	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	2.0	20
11	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health, 2016, 19, 1009-1015.	0.3	24
12	Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Radiotherapy and Oncology, 2016, 118, 267-271.	0.6	36
13	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	3.0	8
14	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.	6.4	137
15	Pembrolizumab for melanoma- safety profile and future trends. Expert Opinion on Drug Safety, 2016, 15, 727-729.	2.4	9
16	CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. Tumor Biology, 2016, 37, 13077-13090.	1.8	36
17	Patient-derived tumor xenograft models for melanoma drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 895-906.	5.0	20
18	Immunotherapy in Lung Cancer. Cancer Treatment and Research, 2016, 170, 203-223.	0.5	8
19	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. Journal of the Neurological Sciences, 2016, 370, 13-17.	0.6	23

ARTICLE IF CITATIONS # Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 20 2.0 24 2016, 8, 775-784. Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. 11.7 39 Biotechnology Ádvances, 2016, 34, 565-577. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous 22 1.4 140 measurement of NF-Î<sup>2</sup>B, NFAT and AP-1. Journal of Immunological Methods, 2016, 430, 10-20. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic 148 signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 770-784. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint 24 4.0 39 Inhibition. Current Oncology Reports, 2016, 18, 21. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22, 886-894. Targeting protein kinase-b3 (akt3) signaling in melanoma. Expert Opinion on Therapeutic Targets, 2017, 26 3.4 16 21, 273-290. Making Targeted Therapy Compatible with Checkpoint Immunotherapy. Trends in Biotechnology, 2017, 35, 582-584. Current status of research and treatment for non-small cell lung cancer in never-smoking females. 28 3.4 66 Cancer Biology and Therapy, 2017, 18, 359-368. Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. Clinical and Experimental Dermatology, 2017, 1.3 42, 614-621. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. Oncology, 2017, 93, 30 1.9 31 387-394. The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. Biochemistry, 2017, 56, 5428-5439. Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human 32 3.0 72 primates. Bioorganic and Medicinal Chemistry, 2017, 25, 5407-5414. Preclinical Pharmacokinetics and Biodistribution Studies of <sup>89</sup>Zr-Labeled Pembrolizumab. 5.0 Journal of Nuclear Medicine, 2017, 58, 162-168. Multispectral imaging for highly accurate analysis of tumourâ€infiltrating lymphocytes in primary 34 2.9 14 melanoma. Histopathology, 2017, 70, 643-649. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 2017, 8, 410-416. New Frontiers in Melanoma Epigeneticsâ€"The More We Know, the More We Don't Know. Epigenomes, 36 1.8 6 2017, 1, 3. Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin. Frontiers in 2.8 24 Oncology, 2017, 7, 61.

ARTICLE IF CITATIONS # Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. Evidence-based 38 1.2 25 Complementary and Alternative Medicine, 2017, 2017, 1-8. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Dermato-Venereologica, 2017, 97, 395-396. 1.3 39 40 Patient-Derived Xenografting of Human Melanoma., 2017, , 341-363. 0 Data-DrivenÂMethods for Advancing Precision Oncology. Current Pharmacology Reports, 2018, 4, 3.0 145-156. Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable 42 4.6 18 therapeutic target. Oncolmmunology, 2018, 7, e1452583. The emerging world of breast cancer immunotherapy. Breast, 2018, 37, 200-206. 2.2 Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and 44 4.7 51 Simulation and Cost Analysis. Clinical Pharmacology and Therapeutics, 2018, 103, 582-590. Mesothelinâ€'targeted second generation CARâ€'T cells inhibit growth of mesothelinâ€'expressing tumors 1.8 21 inï¿1/2vivo. Experimental and Therapeutic Medicine, 2019, 17, 739-747. Low-dose cyclophosphamide depletes circulating  $na\tilde{A}$  ve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. 30 46 4.6 Oncolmmunology, 2018, 7, e1474318. BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by 5.6 118 combined photothermal therapy and immunotherapy. Nanoscale, 2018, 10, 21640-21647. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of 48 3.030 pancreatic cancer. Cellular Immunology, 2018, 329, 31-40. Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315. 2.8 244 The Emerging Therapeutic Landscape of Advanced Melanoma. Current Pharmaceutical Design, 2018, 24, 50 1.9 16 549-558. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular 4.1 Dynamics Simulations. International Journal of Molecular Sciences, 2018, 19, 1984. 53 Economics of the Pharmaceutical Industry. Journal of Economic Literature, 2018, 56, 397-449. 6.5 84 Medication use evaluation of programmed death-1 inhibitors in a veteran population. Journal of 54 Oncology Pharmacy Practice, 2019, 25, 1066-1075. Circadian Rhythms and Personalized Melanoma Therapy. Europeanization and Globalization, 2019, , 55 0.10 327-340. Personalized Medicine in Healthcare Systems. Europeanization and Globalization, 2019, , . 0.1

#	Article	IF	CITATIONS
57	Effect and biomarker of Nivolumab for non–small-cell lung cancer. Biomedicine and Pharmacotherapy, 2019, 117, 109199.	5.6	22
58	NK Cell-Fc Receptors Advance Tumor Immunotherapy. Journal of Clinical Medicine, 2019, 8, 1667.	2.4	17
59	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
60	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Frontiers in Pharmacology, 2019, 10, 609.	3.5	60
61	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. International Journal of Cardiology, 2019, 292, 171-179.	1.7	44
62	Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. Molecular Therapy - Oncolytics, 2019, 13, 93-106.	4.4	107
63	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	4.8	177
64	Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. Translational Medicine Communications, 2019, 4, .	1.4	3
65	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	2.0	17
66	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integrative Cancer Therapies, 2019, 18, 153473541982709.	2.0	2
67	A STUDY OF METHOD DEVELOPMENT, VALIDATION AND FORCED DEGRADATION FOR SIMULTANEOUS QUANTIFICATION OF CABOZANTINIB AND NIVOLUMAB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC. Asian Journal of Pharmaceutical and Clinical Research, 2019, , 102-106.	0.3	1
68	Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti–programmed death 1 antibody. European Journal of Cancer, 2019, 106, 193-195.	2.8	18
69	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. Journal of Pathology: Clinical Research, 2019, 5, 53-62.	3.0	7
70	Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold. European Journal of Medicinal Chemistry, 2020, 186, 111856.	5.5	34
71	Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. Cancers, 2020, 12, 2799.	3.7	8
72	Immunotherapy for acute myeloid leukemia: the dawn of a new era?. Annals of Blood, 2020, 5, 13-13.	0.4	0
73	Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach. Dermatologic Therapy, 2020, 33, e14193.	1.7	8
74	SAT-LB112 An Unusual Case of Ipilimumab/Nivolumab Induced Fulminant Diabetic Ketoacidosis (DKA) in a Non Diabetic Patient - a Case Report. Journal of the Endocrine Society, 2020, 4, .	0.2	1

#	Article	IF	CITATIONS
75	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. OncoImmunology, 2020, 9, 1760705.	4.6	11
76	Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature. Journal of Neuroimmunology, 2020, 341, 577184.	2.3	27
77	Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review. Cancer Medicine, 2020, 9, 1603-1612.	2.8	17
78	Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. Cancers, 2020, 12, 331.	3.7	27
79	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers, 2020, 12, 863.	3.7	18
80	Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma. Cancer Immunology, Immunotherapy, 2021, 70, 1405-1417.	4.2	19
81	Leukemia: Trends in treatment and how close we have achieved eradication. , 2021, , 547-587.		0
82	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clinical Science, 2021, 135, 703-724.	4.3	18
83	Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. Pathology Research and Practice, 2021, 220, 153390.	2.3	2
84	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. Cancers, 2021, 13, 2312.	3.7	11
85	Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. Journal of Pancreatology, 2021, 4, 106-114.	0.9	3
86	MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer. Journal of Clinical Medicine, 2021, 10, 2872.	2.4	39
87	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers, 2021, 13, 2858.	3.7	12
88	Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World Journal of Gastroenterology, 2021, 27, 2727-2757.	3.3	28
89	Pharmacogenomicâ€Guided Therapy in Colorectal Cancer. Clinical Pharmacology and Therapeutics, 2021, 110, 616-625.	4.7	14
90	Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell International, 2021, 21, 426.	4.1	7
91	Cutaneous adverse events caused by immune checkpoint inhibitors. Journal of the American Academy of Dermatology, 2021, 85, 956-966.	1.2	59
92	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 664-677.	1.6	7

#	Article	IF	CITATIONS
93	Immunotherapy of cancer. , 2021, , 141-174.		0
94	Challenges of Immunotherapy. , 2016, , 419-434.		1
96	BSA-modified gold nanorods for combined photothermal therapy and immunotherapy of melanoma. , 2019, , .		3
97	Nanomedicine in Melanoma: Current Trends and Future Perspectives. , 0, , 143-159.		5
98	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. Oncotarget, 2016, 7, 76891-76901.	1.8	9
99	Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF <i>V600E</i> -mutant melanoma. Oncotarget, 2018, 9, 10905-10919.	1.8	17
100	BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget, 2016, 7, 17665-17680.	1.8	13
101	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. Annals of Translational Medicine, 2016, 4, 201-201.	1.7	5
102	Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. International Journal of Critical Illness and Injury Science, 2017, 7, 177.	0.6	13
103	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1167-1175.	0.9	51
104	Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. Cureus, 2017, 9, e1943.	0.5	8
105	Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach. Frontiers in Oncology, 2021, 11, 704607.	2.8	16
106	New Progress in Breast Cancer Immunotherapy. Advances in Clinical Medicine, 2018, 08, 47-52.	0.0	0
107	Clinicopathological correlation of immune response in human cancers. Oncotarget, 2019, 10, 5859-5870.	1.8	0
108	Pembrolizumab: The Nut Cracker. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 393-396.	0.2	0
109	Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma. Cureus, 2021, 13, e19110.	0.5	1
110	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	1.2	4
111	Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction. Bioorganic and Medicinal Chemistry Letters, 2022, 63, 128647.	2.2	4

#	Article	IF	CITATIONS
113	Vitiligo in a patient with metastatic melanoma receiving human immunoglobulin G4 monoclonal antibodynivolumab treatment. Turkderm, 2022, 56, 135-137.	0.1	0
114	Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma. Molecular Pharmaceutics, 2022, 19, 4487-4505.	4.6	11
115	A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer, 2022, 22, .	2.6	1
116	An <i>in silico</i> model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. Journal of the Royal Society Interface, 2023, 20, .	3.4	2
117	Can Baseline [ <sup>18</sup> F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study. Cancer Biotherapy and Radiopharmaceuticals, 2023, 38, 256-267.	1.0	0
118	Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. , 2023, 11, e006290.		14
119	Clinical updates in neoadjuvant immunotherapy for melanoma before surgery. Expert Review of Clinical Immunology, 0, , 1-17.	3.0	1
120	Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field. Cancers, 2023, 15, 4125.	3.7	1
121	In Vitro Antiproliferative Effect of Cannabis Extract PHEC-66 on Melanoma Cell Lines. Cells, 2023, 12, 2450.	4.1	1
122	Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective. Biomedicine and Pharmacotherapy, 2024, 171, 116132.	5.6	0
124	Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches. Cancer Journal (Sudbury, Mass ), 2024, 30, 54-70.	2.0	0